Samsara BioCapital, LLC — 13F Holdings & Portfolio
CIK 1744967 · latest 13F-HR filed 2026-08-14
Samsara BioCapital, LLC manages $1.22B in 13F-reported U.S. long-equity assets across 24 reported positions as of its 2026-06-30 13F-HR filing. Its largest disclosed positions are SRRK (31.16%), ALMS (14.67%), MLYS (13.01%). Quarter over quarter (versus its 2026-03-31 filing) the fund opened 4 new positions and exited 2; 10 existing positions rose in reported value and 8 fell.
AUM is the long-equity portion reported on Form 13F-HR. Excludes short positions, cash, foreign holdings, and non-13F assets. For informational purposes only — not investment advice.
Long-equity book
Distinct positions
Filed 2026-08-14
vs 2026-03-31
Portfolio charts
Latest quarter's book, what changed, and how the portfolio has evolved across filings.
Portfolio map
Q2 26Box size = position value; colour = change in share count vs the prior quarter (green added, red trimmed, blue new). Rows split across managers or share classes are combined. Click a box for the stock.
Sector mix
% of 13F valueSectors from each company's SIC code; funds and ETFs grouped separately.
Biggest buys and sells
Q1 26 → Q2 26Estimated from the change in shares held × the quarter-end price, so price moves alone don't count as buying. New and exited positions are included.
13F assets and positions
4 quartersTotal reported 13F value (bars) and number of positions (line) each quarter. Value changes include market moves.
Top positions over time
reported valueThe eight largest current positions, valued at each quarter end.
Concentration
top 10 = 90.5%Cumulative share of the portfolio held in the largest N positions.
| Name | Title / Status | Ownership | Type |
|---|---|---|---|
| AKKARAJU, SRINIVAS Control | MANAGER OF SAMSARA BIOCAPITAL, LLC | 75% or more | Individual |
| DYBBS, MICHAEL, PHILIP Control | PARTNER | Less than 5% | Individual |
| AHMAD, MIRAN, NASRUDDIN | CHIEF FINANCIAL OFFICER | Less than 5% | Individual |
| HUSSAIN, ABRAR, AHMED | GENERAL COUNSEL AND CHIEF COMPLIANCE OFFICER | Less than 5% | Individual |
Quarter-over-quarter changes
Changes in reported position value vs the prior 13F, so price moves count too, not just shares bought or sold.
Top Adds (vs prior quarter)
- SCHOLAR ROCK HLDG CORP$40.3M +11.9%
- ALUMIS INC$38.8M +27.7%
- SEPTERNA INC$29.8M +39.4%
- NEUROGENE INC$19.4M +56.0%
- SUTRO BIOPHARMA INC$8.8M +33.3%
Top Trims
- KALARIS THERAPEUTICS INC-$22.3M -29.8%
- SPYGLASS PHARMA INC-$7.7M -14.1%
- INVENTIVA SA-$5.0M -17.2%
- UPSTREAM BIO INC-$4.2M -63.1%
- GOSSAMER BIO INC-$1.2M -49.9%
New Positions
- ALAMAR BIOSCIENCES INC$67.2M
- PARABILIS MEDICINES INC$15.2M
- ARTIVA BIOTHERAPEUTICS INC$9.3M
- ELOXX PHARMACEUTICALS INC$5.6M
Samsara BioCapital, LLC Holdings (2026-06-30)
Rows tagged Call or Put are options positions, not stock. Per SEC Form 13F-HR, Value shows the notional value of the underlying (shares covered × underlying price), not the option premium. Shares is the number of underlying shares covered (divide by 100 for contract count).
| # | Issuer | Symbol | CUSIP | Value | Weight | Shares | Type |
|---|---|---|---|---|---|---|---|
| 1 | SCHOLAR ROCK HLDG CORP | SRRK | 80706P103 | $379.4M | 31.16% | 6,897,652 | SH |
| 2 | ALUMIS INC | ALMS | 022307102 | $178.6M | 14.67% | 6,345,219 | SH |
| 3 | MINERALYS THERAPEUTICS INC | MLYS | 603170101 | $158.4M | 13.01% | 5,871,018 | SH |
| 4 | SEPTERNA INC | SEPN | 81734D104 | $105.5M | 8.66% | 3,149,128 | SH |
| 5 | ALAMAR BIOSCIENCES INC | ALMR | 010911105 | $67.2M | 5.52% | 2,480,310 | SH |
| 6 | NEUROGENE INC | NGNE | 64135M105 | $54.0M | 4.44% | 1,717,127 | SH |
| 7 | KALARIS THERAPEUTICS INC | KLRS | 482929106 | $52.4M | 4.31% | 12,881,175 | SH |
| 8 | SPYGLASS PHARMA INC | SGP | 85220G109 | $47.0M | 3.86% | 2,109,953 | SH |
| 9 | SUTRO BIOPHARMA INC | STRO | 869367201 | $35.3M | 2.90% | 1,062,872 | SH |
| 10 | INVENTIVA SA | IVA | 46124U107 | $23.9M | 1.96% | 6,314,805 | SH |
| 11 | JADE BIOSCIENCES INC | JBIO | 008064206 | $16.4M | 1.34% | 736,237 | SH |
| 12 | PARABILIS MEDICINES INC | PBLS | 698955101 | $15.2M | 1.25% | 556,044 | SH |
| 13 | VTV THERAPEUTICS INC | VTVT | 918385204 | $11.2M | 0.92% | 298,496 | SH |
| 14 | AQUESTIVE THERAPEUTICS INC | AQST | 03843E104 | $10.4M | 0.85% | 2,500,000 | SH |
| 15 | NKARTA INC | NKTX | 65487U108 | $9.9M | 0.82% | 3,507,666 | SH |
| 16 | ARTIVA BIOTHERAPEUTICS INC | ARTV | 04317A107 | $9.3M | 0.76% | 954,861 | SH |
| 17 | RANI THERAPEUTICS HLDGS INC | RANI | 753018100 | $7.9M | 0.65% | 10,369,159 | SH |
| 18 | AGOMAB THERAPEUTICS NV | AGMB | 00860C102 | $7.8M | 0.64% | 600,000 | SH |
| 19 | ABIVAX SA | ABVX | 00370M103 | $7.3M | 0.60% | 55,095 | SH |
| 20 | X4 PHARMACEUTICALS INC | XFOR | 98420X202 | $6.5M | 0.54% | 1,395,587 | SH |
| 21 | ELOXX PHARMACEUTICALS INC | ELOX | 29014R301 | $5.6M | 0.46% | 400,000 | SH |
| 22 | COHERUS ONCOLOGY INC | CHRS | 19249H103 | $4.8M | 0.39% | 3,428,571 | SH |
| 23 | UPSTREAM BIO INC | UPB | 91678A107 | $2.4M | 0.20% | 353,717 | SH |
| 24 | GOSSAMER BIO INC | GOSS | 38341P102 | $1.2M | 0.10% | 7,222,559 | SH |
| Period | Filed | AUM | Holdings | Accession |
|---|---|---|---|---|
| 2026-06-30 | 2026-08-14 | $1.22B | 24 | 0001744967-26-000010 |
| 2026-03-31 | 2026-05-15 | $1.03B | 22 | 0001744967-26-000005 |
| 2025-12-31 | 2026-02-17 | $969.3M | 21 | 0001744967-26-000002 |
| 2025-09-30 | 2025-11-14 | $765.9M | 27 | 0001744967-25-000004 |
PALO ALTO, CA 94301